Here are the DEF 14A proxy statements from CG Oncology, Inc. (CGON) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CGON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGON filings page.
CG Oncology, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026 at 10:00 a.m. Pacific Time. Holders of common stock at the close of business on April 7, 2026, when 88,009,980 shares were outstanding, may vote.
Stockholders will elect two Class II directors, Christina Rossi and Victor Tong Jr., to terms ending at the 2029 annual meeting, ratify Ernst & Young LLP as independent auditor for 2026, approve on an advisory basis executive compensation, and choose how often future advisory votes on pay should occur.
The company highlights its classified board, independent committee structure, risk oversight framework, and use of performance-based and equity incentives. The meeting will be conducted exclusively online via webcast, with voting and questions available through the designated proxy website.